Moleculin Biotech, Inc. announced the immediate exercise of outstanding warrants, resulting in gross proceeds of approximately $6.0 million.
Roth Capital Partners is the financial advisor for the transaction.
The company will issue new unregistered warrants for the cash exercise of existing warrants.
Gross Proceeds
Approximately $6.0 million expected from the exercise of outstanding warrants.
New Warrants
Up to 64,864,864 shares of common stock exercisable at an exercise price of $0.55 per share.
Use of Proceeds
Intended for working capital and general corporate purposes.
Registration Statement
The company has agreed to file a registration statement with the SEC covering the resale of shares issuable upon exercise of new warrants.
- The transaction is expected to close on August 28, 2025, subject to customary closing conditions.
- Net proceeds from the offering will be used for working capital and general corporate purposes.
Moleculin Biotech's exercise of warrants for $6.0 million reinforces its financial position for future operations and growth.